Literature DB >> 24091438

Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.

Hiroaki Nishimura1, Hideki Enokida, Satoshi Nagano, Masahiro Yokouchi, Hiroshi Hayami, Setsuro Komiya, Masayuki Nakagawa.   

Abstract

Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide. The most serious complications among the ifosfamide intoxications are neurotoxicity and nephrotoxicity. We report on a patient who suffered from ifosfamide-induced neurotoxicity and nephrotoxicity and rhabdomyolysis after chemotherapy, and was successfully treated with blood purification therapy. The patient had osteosarcoma with multiple lung metastases, wherein the chemotherapy included ifosfamide (3 g/m(2)) and VP-16 (60 mg/m(2)) per day for 3 days. The first day after chemotherapy, the patient experienced impaired consciousness and renal function. Based on the clinical course and laboratory data, the diagnosis was ifosfamide-induced neurotoxicity and the acute kidney injury caused by ifosfamide-induced nephrotoxicity and rhabdomyolysis. As a detoxification treatment, blood purification procedures were performed daily for 3 days. Thirty-six hours after the first hemodialysis session, the symptoms of neurotoxicity disappeared. In the lead-up to the 10th day following intoxication, the serum creatinine recovered to the baseline level. Serum ifosfamide concentration decreased from 41.9 to 12.1 ng/ml by the second session of blood purification. Despite the absence of an established detoxification method when complications present simultaneously, blood purification therapy should be considered for treating severe concurrent neurotoxicity and nephrotoxicity and rhabdomyolysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24091438     DOI: 10.1007/s10047-013-0733-1

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  21 in total

1.  Haemoperfusion combined with haemodialysis in ifosfamide intoxication.

Authors:  R Fiedler; F Baumann; B Deschler; B Osten
Journal:  Nephrol Dial Transplant       Date:  2001-05       Impact factor: 5.992

2.  Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.

Authors:  Allen M Goorin; Michael B Harris; Mark Bernstein; William Ferguson; Meenakshi Devidas; Gene P Siegal; Mark C Gebhardt; Cindy L Schwartz; Michael Link; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

3.  Severe rhabdomyolysis as a complication of high-dose chemotherapy in a patient with advanced testicular cancer.

Authors:  S Hoshi; A Itoh; S Kato; K Suzuki; S Kawamura; S Orikasa
Journal:  Int J Urol       Date:  1999-01       Impact factor: 3.369

4.  Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.

Authors:  A Suarez; H McDowell; P Niaudet; E Comoy; F Flamant
Journal:  J Clin Oncol       Date:  1991-12       Impact factor: 44.544

5.  Dechloroethylation of ifosfamide and neurotoxicity.

Authors:  M P Goren; R K Wright; C B Pratt; F E Pell
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

6.  Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.

Authors:  J S Miser; T J Kinsella; T J Triche; M Tsokos; P Jarosinski; R Forquer; R Wesley; I Magrath
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

7.  Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.

Authors:  R Rossi; A Gödde; A Kleinebrand; M Riepenhausen; J Boos; J Ritter; H Jürgens
Journal:  J Clin Oncol       Date:  1994-01       Impact factor: 44.544

8.  Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study.

Authors:  F H Kung; C B Pratt; R A Vega; N Jaffe; D Strother; M Schwenn; R Nitschke; A C Homans; C T Holbrook; B Golembe
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

9.  Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

Authors:  M Mohrmann; S Ansorge; U Schmich; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

Review 10.  Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.

Authors:  J Pelgrims; F De Vos; J Van den Brande; D Schrijvers; A Prové; J B Vermorken
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more
  1 in total

1.  Journal of Artificial Organs 2014: the year in review.

Authors:  Y Sawa; K Matsuda; E Tatsumi; G Matsumiya; T Abe; K Fukunaga; A Kishida; K Kokubo; T Masuzawa; A Myoui; M Nishimura; T Nishimura; T Nishinaka; E Okamoto; S Tokunaga; T Tomo; T Tsukiya; Y Yagi; T Yamaoka
Journal:  J Artif Organs       Date:  2015-02-21       Impact factor: 1.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.